TY - JOUR
T1 - Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION® long QT syndrome genetic test
AU - Kapplinger, Jamie D.
AU - Tester, David J.
AU - Salisbury, Benjamin A.
AU - Carr, Janet L.
AU - Harris-Kerr, Carole
AU - Pollevick, Guido D.
AU - Wilde, Arthur A.M.
AU - Ackerman, Michael J.
N1 - Funding Information:
Kapplinger and Tester contributed equally to this work. Supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program (Dr. Ackerman), and the Leducq Foundation, Grant 05 CVD, Alliance against Sudden Cardiac death (Dr. Wilde). Dr. Ackerman is a consultant for PGxHealth. Intellectual property derived from Dr. Ackerman's research program resulted in license agreements in 2004 between Mayo Clinic Health Solutions (formerly Mayo Medical Ventures) and PGxHealth (formerly Genaissance Pharmaceuticals).
PY - 2009/9
Y1 - 2009/9
N2 - Background: Long QT syndrome (LQTS) is a potentially lethal, highly treatable cardiac channelopathy for which genetic testing has matured from discovery to translation and now clinical implementation. Objectives: Here we examine the spectrum and prevalence of mutations found in the first 2,500 unrelated cases referred for the FAMILION® LQTS clinical genetic test. Methods: Retrospective analysis of the first 2,500 cases (1,515 female patients, average age at testing 23 ± 17 years, range 0 to 90 years) scanned for mutations in 5 of the LQTS-susceptibility genes: KCNQ1 (LQT1), KCNH2 (LQT2), SCN5A (LQT3), KCNE1 (LQT5), and KCNE2 (LQT6). Results: Overall, 903 referral cases (36%) hosted a possible LQTS-causing mutation that was absent in >2,600 reference alleles; 821 (91%) of the mutation-positive cases had single genotypes, whereas the remaining 82 patients (9%) had >1 mutation in ≥1 gene, including 52 cases that were compound heterozygous with mutations in >1 gene. Of the 562 distinct mutations, 394 (70%) were missense, 428 (76%) were seen once, and 336 (60%) are novel, including 92 of 199 in KCNQ1, 159 of 226 in KCNH2, and 70 of 110 in SCN5A. Conclusion: This cohort increases the publicly available compendium of putative LQTS-associated mutations by >50%, and approximately one-third of the most recently detected mutations continue to be novel. Although control population data suggest that the great majority of these mutations are pathogenic, expert interpretation of genetic test results will remain critical for effective clinical use of LQTS genetic test results.
AB - Background: Long QT syndrome (LQTS) is a potentially lethal, highly treatable cardiac channelopathy for which genetic testing has matured from discovery to translation and now clinical implementation. Objectives: Here we examine the spectrum and prevalence of mutations found in the first 2,500 unrelated cases referred for the FAMILION® LQTS clinical genetic test. Methods: Retrospective analysis of the first 2,500 cases (1,515 female patients, average age at testing 23 ± 17 years, range 0 to 90 years) scanned for mutations in 5 of the LQTS-susceptibility genes: KCNQ1 (LQT1), KCNH2 (LQT2), SCN5A (LQT3), KCNE1 (LQT5), and KCNE2 (LQT6). Results: Overall, 903 referral cases (36%) hosted a possible LQTS-causing mutation that was absent in >2,600 reference alleles; 821 (91%) of the mutation-positive cases had single genotypes, whereas the remaining 82 patients (9%) had >1 mutation in ≥1 gene, including 52 cases that were compound heterozygous with mutations in >1 gene. Of the 562 distinct mutations, 394 (70%) were missense, 428 (76%) were seen once, and 336 (60%) are novel, including 92 of 199 in KCNQ1, 159 of 226 in KCNH2, and 70 of 110 in SCN5A. Conclusion: This cohort increases the publicly available compendium of putative LQTS-associated mutations by >50%, and approximately one-third of the most recently detected mutations continue to be novel. Although control population data suggest that the great majority of these mutations are pathogenic, expert interpretation of genetic test results will remain critical for effective clinical use of LQTS genetic test results.
KW - Genetic testing
KW - Long QT syndrome
KW - Potassium channels
KW - Sodium channels
UR - http://www.scopus.com/inward/record.url?scp=68949209933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68949209933&partnerID=8YFLogxK
U2 - 10.1016/j.hrthm.2009.05.021
DO - 10.1016/j.hrthm.2009.05.021
M3 - Article
C2 - 19716085
AN - SCOPUS:68949209933
SN - 1547-5271
VL - 6
SP - 1297
EP - 1303
JO - Heart rhythm
JF - Heart rhythm
IS - 9
ER -